Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Category

HIV/AIDS

53 articles in this topic.

Articles in this category

FDA Launches Global Reliance Disclosure Program for Approval Packages

11/18/2026

FDA Launches Global Reliance Disclosure Program for Approval Packages

The FDA's Global Reliance Disclosure Program lets companies pass minimally redacted approval packages to regulators outside the US. Lenacapavir is the launch case, and the FDA intends to widen the program in January 2027. #SyenzaNews #MarketAccess
Read Article →
Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion

11/17/2026

Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion

The three-month dapivirine vaginal ring has received a positive EMA scientific opinion, with the ring replaced four times per year. #SyenzaNews #HIVprevention #MarketAccess
Read Article →
Generic lenacapavir HIV prevention gets FDA tentative approval

11/3/2026

Generic lenacapavir HIV prevention gets FDA tentative approval

Dr. Reddy's has FDA tentative approval for generic lenacapavir HIV prevention, priced at US$40 per person per year across 120 countries. #SyenzaNews #HIVprevention #MarketAccess
Read Article →
Antiretroviral Tender Awards Declared Invalid by Pretoria Court

10/26/2026

Antiretroviral Tender Awards Declared Invalid by Pretoria Court

A Pretoria court has declared invalid the antiretroviral tender awards for two items and ordered the health department to redo the split within 120 days. Cipla's review succeeded on all five grounds, while Hetero's challenge was dismissed with attorney-and-client costs. #SyenzaNews #SouthAfrica #HIV
Read Article →
NICE Draft Guidance Rejects Lenacapavir for HIV PrEP in England

9/11/2026

NICE Draft Guidance Rejects Lenacapavir for HIV PrEP in England

NICE has opened consultation on draft guidance that does not recommend lenacapavir for HIV PrEP, finding the six-monthly injection is not value for money for the NHS in England. #SyenzaNews #HTA #HIV #PrEP #MarketAccess
Read Article →
South Africa Initiates 55,123 People on Twice-Yearly Lenacapavir PrEP

9/9/2026

South Africa Initiates 55,123 People on Twice-Yearly Lenacapavir PrEP

South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme's first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess
Read Article →
Aspen Exits Lenacapavir Local Manufacturing, Backs Merck’s Monthly Oral PrEP

9/7/2026

Aspen Exits Lenacapavir Local Manufacturing, Backs Merck’s Monthly Oral PrEP

Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck's once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess
Read Article →
South Africa Shortlists Local Firms to Produce Lenacapavir HIV Prevention Shot

8/6/2026

South Africa Shortlists Local Firms to Produce Lenacapavir HIV Prevention Shot

How is South Africa advancing local production of cutting-edge HIV treatments? The country has shortlisted manufacturers for Lenacapavir, paving the way for greater domestic capacity, improved access, and stronger pharmaceutical supply chains across the region. Explore how this step supports broader drug development goals. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess
Read Article →
Future HIV Control in Africa Demands Bold Leadership

7/31/2026

Future HIV Control in Africa Demands Bold Leadership

Is Africa's HIV future at a crossroads? The Africa HIV Control Working Group's 2026 webinar spotlighted UNAIDS, UNICEF & health leaders on domestic financing, sovereignty, integrated systems & community leadership to build resilient HIV control. Read more & join the push for bold action. #HIVControl #AfricaHealth #BoldLeadership #UNAIDS #GlobalHealth
Read Article →
Aspen’s Licensing Deal Aims to Speed HIV Prevention Access in Africa

7/27/2026

Aspen’s Licensing Deal Aims to Speed HIV Prevention Access in Africa

How can smart licensing cut years off HIV prevention launches in Africa? Aspen’s latest agreements are shrinking launch lags by enabling faster local production and regulatory pathways for prevention therapies. This approach is expanding access where it’s needed most. Read the full story on how these deals are reshaping timelines and equity in HIV care. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #innovation
Read Article →
Weekly Islatravir Lenacapavir HIV Trial Confirms Sustained Suppression

7/22/2026

Weekly Islatravir Lenacapavir HIV Trial Confirms Sustained Suppression

💊 Could once-weekly dosing redefine HIV treatment adherence? A new trial confirms that islatravir combined with lenacapavir delivers sustained viral suppression, offering a promising step toward simpler, longer-acting regimens for people living with HIV. Read the full analysis and implications for drug development. #SyenzaNews #clinicaltrials #pharmaceuticals #innovation
Read Article →
PIMART South Africa HIV pharmacists Boost Treatment Access

7/14/2026

PIMART South Africa HIV pharmacists Boost Treatment Access

💊 How are pharmacists expanding HIV treatment access across South Africa? Through the PIMART initiative, trained pharmacists can now initiate antiretroviral therapy, closing critical gaps in care and reaching more patients in underserved communities. Discover how this model is reshaping service delivery and outcomes. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #innovation
Read Article →

Related topics